



B/
IDW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Group Art Unit 1624

In re

Patent Application of

Niall Morrison Barr Martin, et al.

Application No. 10/021,506

Confirmation No.: 8516

Filed: October 30, 2001

Examiner: Richard L. Raymond

“PHTHALAZINONE DERIVATIVES”

I, Julie Mallder, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.

Julie Mallder
Signature

March 17, 2005
Date of Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR §1.97(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08A and PTO/SB/08B. Copies of the references are enclosed..

Citation of these references is respectfully requested.

An RCE in this application was filed March 16, 2005. No fee is believed to be due in connection with this communication. In the event that applicants have overlooked the need for a fee, please charge Deposit Account No. 50-0842 with the required fee.


No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,


Charlene L. Yager
Reg. No. 48,887

File No. 065435-9009

Michael Best & Friedrich LLP
One South Pinckney Street
P. O. Box 1806
Madison, WI 53701-1806
608.257.3501



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	2	Application Number	10/021,506
-------	---	----	---	--------------------	------------

Application Number	10/021,506
Filing Date	October 30, 2001
First Named Inventor	Niall Morrison Barr Martin
Group Art Unit	1624
Examiner Name	Richard L. Raymond
Attorney Docket Number	065435-9009

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document

FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	EP	0705903	Myriad Genetics, Inc. et al.	4/10/1996		
	FR	2262513	Delalande S.A.	9/26/1975		
	GB	2384776	Kudos Pharmaceuticals Limited et al.	3/3/2004		
	JP	62-252774 (abstract)	Fujisawa Pharmaceutical Co., Ltd.	11/4/1987		
	WO	95/24379	Cancer Research Campaign Technology Limited	9/14/1995		
	WO	01/12199	Case Western Reserve University	2/22/2001		
	WO	01/16136	Agouron Pharmaceuticals, Inc. et al.	3/8/2001		
	WO	01/21615	Yamanouche Pharmaceutical Co., Ltd.	3/29/2001		Y
	WO	01/23390	BASF Aktiengesellschaft	4/5/2001		Y

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/021,506
				Filing Date	October 30, 2001
				First Named Inventor	Niall Morrison Barr Martin
				Group Art Unit	1624
				Examiner Name	Richard L. Raymond
Sheet	2	of	2	Attorney Docket Number	065435-9009

U.S. PATENT DOCUMENTS				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document


FOREIGN PATENT DOCUMENTS						
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	WO	01/57038	BASF Aktiengesellschaft	8/9/2001		Y
	WO	01/79184	Sumitomo Pharmaceuticals Company, Limited	10/25/2001		Y
	WO	01/85686	Cephalon, Inc.	11/15/2001		
	WO	01/85687	BASF AG	11/15/2001		Y
	WO	01/90077	Guilford Pharmaceuticals Inc.	11/29/2001		
	WO	02/068407	Yamanouchi Pharmaceutical Co., Ltd.	9/6/2002		Y
	WO	02/090334	Kudos Pharmaceuticals Ltd. et al.	11/14/2002		
	WO	02/094790	Mitsubishi Pharma Corporation	11/28/2002		Y
	WO	03/007959	Fujisawa Pharmaceutical Co., Ltd.	1/30/2003		
	WO	03/051879	Altana Pharmaceuticals AG	6/26/2003		
	WO	03/055865	Fujisawa Pharmaceutical Co., Ltd.	7/10/2003		
	WO	03/057145	Guilford Pharmaceuticals Inc.	7/17/2003		
	WO	03/070707	Ono Pharmaceutical Co., Ltd.	8/28/2003		Y
	WO	03/070726	Kudos Pharmaceuticals Ltd.	5/10/2002		
	WO	03/080581	Fujisawa Pharmaceutical Co., Ltd.	10/2/2003		
	WO	03/093261	Kudos Pharmaceuticals Ltd. et al.	11/13/2003		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/021,506
				Filing Date	October 30, 2001
				First Named Inventor	Niall Morrison Barr Martin
				Group Art Unit	1624
				Examiner Name	Richard L. Raymond
Sheet	1	of	6	Attorney Docket Number	065435-9009

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		AFFAR, E. B. et al., "Immunodot Blot Method for the Detection of Poly(ADP-ribose) Synthesized in Vitro and in Vivo," <i>Anal. Biochem.</i> , 1998, Vol. 259, No. 2, 280-3
		AL-DABBAGH and SMITH, "Species differences in oxidative drug metabolism: some basic considerations." <i>Archives of toxicology</i> , Supplement. <i>Archiv fur Toxikologie</i> . Supplement, vol. 7, 219-231 (1984)
		AME et al., <i>J. Biol. Chem.</i> , 1999, Vol. 274, 17860-17868
		ANGELL et al., <i>EMBO J.</i> , 1997, Vol. 16, No. 12, 3675-3684
		<i>Applied Biosystems 430A Users Manual</i> , ABI Inc., Foster City, California (book not provided)
		ARNAUDEAU, C. et al., <i>J. Mol. Biol.</i> , 2001, Vol., 307, 1235-45
		BANASIK, M. et al., <i>Mol. Cell Biochem.</i> , 1994, Vol. 138, 185-197
		BODANZSKY, M. and BODANZSKY, A., <i>The Practice of Peptide Synthesis</i> , 1984, Springer Verlag, New York (book not provided)
		BOWMAN et al., "Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU 1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro," <i>British Journal of Cancer</i> , Vol. 84(1), 106-112 (2001)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/021,506
				Filing Date	October 30, 2001
				First Named Inventor	Niall Morrison Barr Martin
				Group Art Unit	1624
				Examiner Name	Richard L. Raymond
Sheet	2	of	6	Attorney Docket Number	065435-9009

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		BUNDGAARD, H., <i>Design of Prodrugs</i> , 1 (1985) Elsevier Science Publishers
		COSI, C., "New inhibitors of poly(ADP-ribose) polymerase and their potential therapeutic targets," <i>Expert Opin. Ther. Patents</i> (2002) 12(7): 1047-1071
		CROOKE, <i>Ann. Rev. Pharmacol. Toxicol.</i> , 1992, Vol. 32, 329-76
		<i>Current Protocols in Molecular Biology</i> , 1992, Eds. AUSUBEL et al., John Wiley & Sons (book not provided)
		DANTZER, F. et al., <i>Biochemistry</i> , 2000, Vol. 39, 7559-69
		DILLON, K. J. et al., <i>J. Biomolecular Screening</i> , 2003, Vol. 8, No. 3, 347-52
		EHRlich et al., <i>Science</i> , 1991, Vol. 252, 1643-50
		<i>From DNA damage and stress signalling to cell death</i> , 2000, Eds. DE MURCIA, G and SHALL, S, Oxford University Press (book not provided)
		GREEN, T. et al., "Protective Groups in Organic Synthesis", 1999, 3 Ed., Wiley (book not provided)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/021,506
				Filing Date	October 30, 2001
				First Named Inventor	Niall Morrison Barr Martin
				Group Art Unit	1624
				Examiner Name	Richard L. Raymond
Sheet	3	of	6	Attorney Docket Number	065435-9009

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		GRIFFIN et al., "The role of inhibitors of poly (ADP-ribose) polymerase as resistance-modifying agents in cancer therapy," <i>Biochim</i> vol. 77, 408-422 (1995)
		HABER, J. E., <i>Trends Biochem. Sci.</i> , 1999, Vol. 24, 271-5
		<i>Handbook of Pharmaceutical Additives</i> , 2001, 2 Ed., Synapse Information Resources Inc., Endicott, New York, USA (book not provided)
		<i>Handbook of Pharmaceutical Excipients</i> , 1994, 2 Ed. (book not provided)
		<i>Hawley's Condensed Chemical Dictionary</i> , 13 th ed., Van Nostrand Reinhold eds. 716 and 825 (1997)
		HOEIJMAKERS, J. H., <i>Nature</i> , 2001, Vol. 411, 366-74
		KERRIGAN, F. et al., Poster at 12 th SCI-RSC Medicinal Chemistry Symposium, Cambridge, 7-10 (2003)
		LEMAY, M. et al., <i>Biotechniques</i> , 1999, Vol. 27, 846-51
		MARTIN, N. et al., <i>J. Photochem. and PhotoBiol. B: Biology</i> , 2001, Vol. 63, 162-170

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/021,506
				Filing Date	October 30, 2001
				First Named Inventor	Niall Morrison Barr Martin
				Group Art Unit	1624
				Examiner Name	Richard L. Raymond
Sheet	4	of	6	Attorney Docket Number	065435-9009

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		MERCOLA, et al., <i>Cancer Gene Therapy</i> , 1995, Vol. 2, No. 1, 47-59
		<i>Molecular Cloning: A Laboratory Manual</i> , 2001, 3 Ed., Sambrook & Russell, Cold Spring Harbor Laboratory Press, New York (book not provided)
		MULLIS et al., <i>Cold Spring Harbor Symp. Quant. Biol.</i> , 1987, Vol. 51, 263-273
		NATHANSON, K. L. et al., <i>Nat. Med.</i> , 2001, Vol. 7, 552-6
		NOEL, G. et al., <i>BMC Cell Biol.</i> , 2003, Vol. 4, 7
		PACHER et al., "The Role of Poly(ADP-Ribose) Polymerase Activation in the Development of Myocardial and Endothelial Dysfunction in Diabetes," <i>Diabetes</i> , 51:514-521 (2002)
		<i>PCR Protocols; A Guide to Methods and Application</i> , 1990, Eds. INNIS et al., Academic Press, New York (book not provided)
		<i>PCR Technology</i> , 1989, Eds. EHRLICH, Stockholm Press, New York (book not provided)
		<i>Remington's Pharmaceutical Sciences</i> , 2000, 20 Ed., Lippincott, Williams & Wilkins (book not provided)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/021,506
				Filing Date	October 30, 2001
				First Named Inventor	Niall Morrison Barr Martin
				Group Art Unit	1624
				Examiner Name	Richard L. Raymond
Sheet	5	of	6	Attorney Docket Number	065435-9009

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		SCHULTZ, N. et al., <i>Nucleic Acids Res.</i> , 2003, Vol. 31, 4959-64
		SHALL, S. et al., <i>Mutat. Res.</i> , 2000, Vol. 460, 1-15
		SILVERMAN, R.B., <i>The Organic Chemistry of Drug Design and Drug Action</i> , 352-400 (1992) Academic Press, Inc.
		SOUTHAN, G.J. and SZABO, C., "Poly (ADP-ribose) polymerase inhibitors," <i>Current Medicinal Chemistry</i> , 10:4, 321-340 (2003)
		STEWART, J. M. and YOUNG, J. D., <i>Solid Phase Peptide Synthesis</i> , 1984, 2 Ed., Pierce Chemical Company, Rockford, Illinois (book not provided)
		SUTO et al., <i>Anticancer Drug Des.</i> , 1991, Vol. 6, 107-17
		THOMPSON, L. H. et al., <i>Mutat. Res.</i> , 2002, Vol. 509, 49-78
		UHLMANN et al., <i>Chem. Rev.</i> , 1990, Vol. 90, 543-584
		VIRAG and SZABO, "The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors," <i>Pharmacological Reviews</i> , vol. 54(3), (2002) 375-429

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/021,506
				Filing Date	October 30, 2001
				First Named Inventor	Niall Morrison Barr Martin
				Group Art Unit	1624
				Examiner Name	Richard L. Raymond
Sheet	6	of	6	Attorney Docket Number	065435-9009

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		VOINNET et al., <i>Nature</i> , 1997, Vol. 389, 553
		WANG, Z.-Q. et al., <i>Genes Dev.</i> , 1997, Vol. 11, 2347-58
		WEST, A.R. "Solid State Chemistry and its Applications" Wiley, New York, 358 and 365 (1988)
		WOOD et al., <i>Science</i> , 2001, Vol. 291, 1284-89

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.